ClinicalTrials.gg

Program

AG-236

A development code.

Its studies are mostly in Polycythemia Vera, led by Agios Pharmaceuticals.

Furthest: phase 3, since Sep 30, 20262 company-led studies, 2 open or runningNext primary completion: Aug 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agios Pharmaceuticals22 open or runningphase 3since Sep 30, 2026Jul 11, 2025Aug 2030phase 3 · NCT07859423

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 11, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT07075640 · 24 enrolled · United States
  2. Sep 30, 2026Phase 3 study in Polycythemia VeraPhase 3 reachedNCT07859423 · 245 planned

Ahead

  1. Aug 2030Primary completion: phase 3 study in Polycythemia VeraNCT07859423

TargetBeta

TMPRSS6 →read by rule
“AG-236 is a small interfering ribonucleic acid (siRNA) targeting transmembrane serine protease 6 (TMPRSS6) intended for the treatment of PV.”study text, by rule · the study

Other programs on TMPRSS6

ProgramCompanyFurthest phaseStudies
sapablursenruleIonis Pharmaceuticalsphase 34
Anti-TMPRSS6 Monoclonal Antibody DISC-3405ruledisc-medicine-incphase 26

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07859423Polycythemia Vera3Not yet recruitingAug 2030245
NCT07075640Healthy Participants · United States1Active, not recruitingFeb 11, 202624

How it is read

Names in the registry

  • “AG-236”, 2 entries

Codes read as this program: AG236.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.